

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 2		ATTY. DOCKET NO.		SERIAL NO.	
		00006.01R		10/057,198	
		APPLICANT			
		Lloyd et al.			
		FILING DATE		GROUP	
		October 26, 2001		3734	
U.S. PATENT DOCUMENTS					
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS
	AA	1,535,486	4/1/1925	Lundy	
	AB	1,803,334	5/1/1931	Lehmann	
	AC	1,864,980	6/1/1932	Curran	
	AD	2,243,669	5/1/1941	Clyne	
	AE	2,469,656	5/1/1949	Lienert	
	AF	2,714,649	8/1/1955	Critzer	
	AG	2,741,812	4/1/1956	Andre	
	AH	2,761,055	8/1/1956	Ike	
	AI	2,887,106	5/1/1959	Robinson	
	AJ	2,898,649	8/1/1959	Murray	
	AK	3,043,977	7/1/1962	Morowitz	
	AL	3,080,624	3/1/1963	Webber III, R.L.	
	AM	3,200,819	8/1/1965	Gilbert	
	AN	3,749,547	7/1/1973	Gregory et al.	
	AO	3,763,347	10/1/1973	Whitaker et al.	
	AP	3,847,650	11/1/1974	Gregory et al.	
	AQ	3,930,796	1/1/1976	Haensel	
	AR	4,020,379	4/1/1977	Manning	
	AS	4,045,156	8/30/1977	Chu et al.	
	AT	4,184,099	1/1/1980	Lindauer et al.	
	AU	4,346,059	8/1/1982	Spector	
	AV	4,556,539	12/1/1985	Spector	
	AW	4,627,963	12/1/1986	Olson, Donald M.	
	AX	4,647,428	3/1/1987	Gyulay	
	AY	4,647,433	3/1/1987	Spector	
	AZ	4,735,358	4/15/1988	Osamo et al.	
	AAA	5,109,180	4/1/1992	Boultonghouse et al.	
	ABB	5,468,936	11/21/1995	Deevi et al.	
	ACC	5,592,934	1/14/1997	Thwaites	
	ADD	5,918,595	7/6/1999	Olsson	
	AEE	6,126,919	10/3/2000	Stefely et al.	
	AFF	6,300,710	10/1/2001	Nakamori	
	AGG	6,501,052	12/31/2002	Cox et al.	
EXAMINER			DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and <u>not</u> considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 2		ATTY. DOCKET NO. 00006.01R		SERIAL NO. 10/057,198		
		APPLICANT Lloyd et al.				
		FILING DATE October 26, 2001		GROUP 3734		
		U.S. Alexza PATENT DOCUMENTS				
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS SUB CLS FILE DATE	
	BA	7,078,016	7/18/2006	Rabinowitz		
	BB	US 2003-0131843	7/17/2003	Lu		
	BC	US 2003-0138508	7/24/2003	Novack et al.		
	BD	US 2004-0009128	1/15/2004	Rabinowitz et al.		
	BE	US 2004-0099266	5/27/2004	Cross et al.		
	BF	US 2006-0120962	6/8/2006	Rabinowitz et al.		
	BG	US 2006-0193788	8/31/2006	Hale et al.		
	BH	US 2006-0286043	12/21/2006	Rabinowitz et al.		
	BI	US 2007-0028916	2/8/2007	Hale et al.		
	BJ	US 2007-0031340	2/8/2007	Hale et al.		
	BK	US 2007-0014737	1/18/2007	Rabinowitz et al.		
	BL	US 2007-0140982	6/21/2007	Every et al.		
	BM	US 2007-0178052	8/2/2007	Rabinowitz et al.		
	BN	11/687,466	3/16/2007	Zaffaroni et al.		
	BO	11/744,799	5/4/2007	Hale et al.		
FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS SUB CLS TRANS ?	
	BP	DE 198 54 007	5/18/2000	Germany		
	BQ	FR 921 852 A	5/21/1947	France		
	BR	FR 2 428 068 A	1/4/1980	France		
	BS	GB 1 366 041	9/11/1974	Great Britain		
	BT	HU 200105B	N/A	Hungary		
	BU	HU 2193292	N/A	Hungary		
	BV	WO 99/055362	11/4/1999	WIPO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	BW	Williams, S. (February 1999). "Rhone-Poulenc Rorer Inc. and Targacept Inc. Announce Alliance to Develop New Drugs to Treat Alzheimer's and Parkinson's Diseases" located at http://www.rpr.rpna.com/ABOUT_RPR/pressrels/1999/990209-targa.html (last visited on January 28, 2000) 1 page.				
	BX	Wood, R.W. et al. (1996). "Methylecgonidine Coats the Crack Particle." <i>Pharmacology Biochemistry & Behavior</i> . 53(1):57-66.				
	BBA	Office Action mailed 12/15/2003 with respect to U.S. Appl. No. 10/057,197				
	BBB	Office Action mailed 03/20/2007 with respect to U.S. Appl. No. 10/146,080				
EXAMINER		/Michael Mendoza/		DATE CONSIDERED 03/12/2009		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						